Presentation Anticoagulant Therapy During Primary PCI for AMI Presenter: Sripal Bangalore November 13, 2014
Presentation SECURITY: Second-Generation DES Implantation Followed by 6- vs 12-Month DAPT Presenter: Antonio Colombo November 10, 2014
Presentation Cardiovascular Interventions 2014 How to Manage Post PCI Antiplatelet Therapy in the Patient on Oral Anticoagulation Presenter: David P. Faxon October 23, 2014
Presentation Impact of Diabetes and Metabolic Syndrome on Acute and Chronic On-Clopidogrel Platelet Reactivity in Patients with Stable CAD Receiving DES Presenter: Laurent Feldman October 06, 2014
Presentation VerifyNow in DIabetes High On-Treatment Platelet Reactivity: Switching from Clopidogrel to Prasugrel Presenter: J.M. Cubero October 06, 2014
Presentation Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding in Stable CAD Presenter: M. Hanon September 30, 2014
Presentation TCT 2014 Con: Follow the Data and Save the Patient! Presenter: Adrian P. Banning, Gregg W. Stone September 16, 2014
Presentation TCT 2014 Pro: Follow the Data - and Save the Money! Presenter: Adrian P. Banning, Rod H. Stables September 16, 2014
Presentation TCT 2014 Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS Presenter: Timothy Henry September 16, 2014
Presentation TCT 2014 Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary Intervention Presenter: Ahmed Rehmani September 16, 2014
Presentation TCT 2014 Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study Presenter: Armando P?rez de Prado September 16, 2014
Presentation TCT 2014 VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_ Presenter: Jos? Mar?a Cubero G?mez September 16, 2014
Presentation TCT 2014 Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE Presenter: Fausto Feres September 16, 2014
Presentation TCT 2014 Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation Presenter: Giulio Stefanini September 16, 2014
Presentation TCT 2014 Impact of platelet reactivity on clopidogrel after PCI with 2nd generation DES on late lumen loss_ Presenter: Naoei Isomura September 16, 2014
Presentation TCT 2014 Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction Presenter: Jun-Hyok Oh September 16, 2014
Presentation TCT 2014 Antiplatelet Effects of Clopidogrel and Aspirin During 6 Months of Follow-up After Stent Implantation: An ADAPT-DES Substudy Presenter: Dietmar Trenk September 16, 2014
Presentation TCT 2014 TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang September 15, 2014